Health Care & Life Sciences » Biotechnology | bioMmune Technologies Inc.

bioMmune Technologies Inc.

bioMmune Technologies Inc.
Stock Exchange Other OTC
EPS
$0.06
Market Cap
$6.31 M
Shares Outstanding
52.02 M
Public Float
-

Profile

Address
400 Burrard Street
Vancouver British Columbia V6C 3A6
Canada
Employees -
Website http://www.pascalbiosciences.com
Updated 07/08/2019
Pascal Biosciences Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. It focuses on the following technologies: Major Histocompatibility Complex I (MHC I), CD74 and Calcium Channel Blockers. The MHC I technology is a molecule that transports normal, abnormal and foreign protein fragments (peptides) to the surface of the cells where the fragments are then exposed to the immune system's T cells.

Financials

View All

Karoly Nikolich
Chairman
Patrick W. Gray
President, Chief Executive Officer & Director